Immunotherapy in tyrosine kinase inhibitor-naive advanced epidermal growth factor receptor-mutant non-small cell lung cancer-driving down a precarious road in driver-mutated lung cancer.
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2018
Metadata
Show full item recordCitation
Tay RY, Ackermann CJ, Califano R. Immunotherapy in tyrosine kinase inhibitor-naive advanced epidermal growth factor receptor-mutant non-small cell lung cancer-driving down a precarious road in driver-mutated lung cancer. Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S377-S80.Journal
Translational Lung Cancer ResearchDOI
10.21037/tlcr.2018.09.16PubMed ID
30705861Additional Links
https://dx.doi.org/10.21037/tlcr.2018.09.16Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.21037/tlcr.2018.09.16
Scopus Count
Collections
Related articles
- Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
- Authors: Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K
- Issue date: 2012 Jun
- Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
- Authors: Pan H, Liu R, Li S, Fang H, Wang Z, Huang S, Zhou J
- Issue date: 2014 Sep
- Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer.
- Authors: Qu L, Li L, Zheng X, Fu H, Tang C, Qin H, Li X, Wang H, Li J, Wang W, Yang S, Wang L, Zhao G, Lv P, Lei Y, Zhang M, Gao H, Song S, Liu X
- Issue date: 2017 Jul 11
- The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
- Authors: Lin JH, Lin D, Xu L, Wang Q, Hu HH, Xu HP, He ZY
- Issue date: 2017 Jan 10